Streetbeat News

Earnings

ABOS

Acumen Pharmaceuticals reported Q2 losses of $(0.28) per share, beating the analyst consensus estimate of $(0.36) by 22.22 percent. However, this is a 12 percent increase in losses compared to the same period last year.

Portfolio Pulse from totan@benzinga.com

August 08, 2023 | 11:02 am

BLUE

bluebird bio (NASDAQ:BLUE) reported Q2 earnings per share of $(0.67), beating the analyst consensus estimate of $(0.71) by 5.63%. However, the company's quarterly sales of $6.89 million missed the analyst consensus estimate of $11.65 million by 40.86%. Despite the sales miss, this represents a 353.59% increase over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:02 am

MASS

908 Devices reported Q2 earnings per share (EPS) of $(0.29), beating the analyst consensus estimate of $(0.33) by 12.12%. However, this is a 11.54% decrease from the same period last year. The company also reported quarterly sales of $12.10 million, surpassing the analyst consensus estimate of $10.36 million by 16.80%, and marking an 8.95% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:01 am

CRNC

Cerence Inc. has projected its Q4 revenue to be between $72M and $76M, which is in line with the estimated $72.06M.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:01 am

HZNP

Horizon Therapeutics (NASDAQ:HZNP) reported Q2 earnings of $1.20 per share, beating the analyst consensus estimate of $1.12 by 7.14%. This is a 12.15% increase from the same period last year. The company also reported quarterly sales of $945.00 million, beating the analyst consensus estimate of $915.60 million by 3.21%, a 7.83% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:01 am

CRNC

Cerence (NASDAQ:CRNC) reported Q3 adjusted EPS of $(0.04), beating the estimate of $(0.15) by 73.33%. However, this is a 109.3% decrease from last year's earnings. The company also reported sales of $61.70M, beating the estimate of $60.83M by 1.43%, but this is a 30.71% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:00 am

NOVT

Novanta reported Q2 adjusted earnings of $0.80 per share, beating the analyst consensus estimate of $0.72 by 11.11%. This is a 2.56% increase over earnings of $0.78 per share from the same period last year. The company also reported quarterly sales of $229.50 million, beating the analyst consensus estimate of $223.82 million by 2.54%. This is a 6.57% increase over sales of $215.36 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:00 am

MAC

Macerich (NYSE:MAC) reported Q2 earnings of $0.40 per share, missing the analyst consensus estimate of $0.42 by 4.76%. This is a 13.04% decrease from the same period last year. The company also reported quarterly sales of $212.37 million, missing the analyst consensus estimate of $218.71 million by 2.90%. This is a 4.06% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:59 am

IFF

International Flavors & Fragrances Inc (IFF) shares dropped by over 22% following worse-than-expected Q2 results and a reduced FY23 outlook. The company reported flat revenue of $2.93 billion, missing the consensus of $3.11 billion. Adjusted EPS of $0.86 also missed the street view of $1.10. IFF lowered its FY23 sales guidance to $11.3 billion-$11.6 billion from around $12.3 billion prior. The company is focusing on enhancing the performance of its Functional Ingredients business and expects to see improvements in 2024.

Portfolio Pulse from Lekha Gupta

August 08, 2023 | 10:58 am

CWEN

Clearway Energy (NYSE:CWEN) reported Q2 earnings of $0.33 per share, a 107.55% increase YoY. The company also reported $406.00 million in sales, a 10.33% increase YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 10:57 am